Keryx Biopharmaceuticals Announces Appointment of Douglass H. Laidlaw, Ph.D.,
as Director, Medical Affairs
Formerly National Director, Medical Science Liaisons of the Renal Division at
NEW YORK, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of medically important pharmaceutical
products for the treatment of renal disease (the "Company"), today announced
the appointment of Douglass H. Laidlaw, Ph.D. to the newly created position of
Director, Medical Affairs, with oversight of the creation and activities of
the Company's Medical Science Liaisons (MSL) team.
Dr. Laidlaw joins the Company from Genzyme/Sanofi (NYSE:SNY), where since 2007
he has worked in the Medical Affairs division, most recently serving as
National Director, Medical Science Liaisons (MSL) of the Renal Division.
During his tenure at Genzyme/Sanofi, Dr. Laidlaw was well recognized for the
strategic development and implementation of many key projects contributing to
the success of the Renal business unit, notably initiatives surrounding
prelaunch activities and generating scientific support aimed at increasing
awareness of acute and chronic kidney disease and its sequelae. Dr. Laidlaw
has extensive experience recruiting, managing and leading field based teams of
Ron Bentsur, the Company's Chief Executive Officer, commented, "We are excited
to be welcoming Dr. Laidlaw to the Company.Dr. Laidlaw brings a proven track
record of success in the development and leadership of a dedicated renal MSL
team, strategic planning capabilities and a vast network of relationships
within the nephrology community. I am confident that he will be an
extraordinary asset as we build out our marketing organization."
Dr. Laidlaw earned his Ph.D. in Physiological Sciences from the University of
Arizona.His academic research career included positions in Biomedical
Engineering at The Cleveland Clinic Foundation and in the Department of
Integrative Physiology at the University of Colorado, Boulder.
Previous to his employment with Genzyme, from 2006-2007, he held the position
of Associate Director Medical Affairs, Medical and Education Liaisons with
Neurocrine Biosciences and was a core member of the team responsible for
creating their Medical Affairs infrastructure. Prior to that time, from
2003-2006, he was a Senior Medical Science Liaison at Serono. He began his
career in the biopharmaceutical industry as a Regional Medical Liaison with
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA), and
the Company has submitted a New Drug Application to the FDA. The Marketing
Authorization Application filing with the European Medicines Agency (EMA) is
pending submission. Zerenex is also in Phase 2 development in the U.S. for the
management of phosphorus and iron deficiency in anemic patients with Stages 3
to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's
Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has
filed its New Drug Application for marketing approval of ferric citrate in
Japan for the treatment of hyperphosphatemia in patients with chronic kidney
disease. Keryx is headquartered in New York City.
Some of the statements included in this press release, particularly those
relating to the commercial opportunity, competitive positioning, and business
prospects for Zerenex, may be forward-looking statements that involve a number
of risks and uncertainties. For those statements, we claim the protection of
the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: the risk that the
NDA and MAA will not be accepted for review by the FDA and EMA, respectively,
due to deficiencies in the application or for other reasons; the risk that the
FDA and EMA ultimately deny approval of the NDA and MAA, respectively; the
risk that SPAs are not a guarantee that the FDA will accept an NDA for filing
or ultimately approve a product candidate following submission; whether the
FDA and EMA will concur with our interpretation of our Phase 3 study results
or the conduct of the study; whether Zerenex, if approved, will be
successfully launched and marketed; and other risk factors identified from
time to time in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as
of the date of this press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not incorporated
by reference into this press release and is included for reference purposes
CONTACT: Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.